Edmonton, Canada

Singh Rajeshwar

This inventor holds 1 USPTO granted patent. Top assignee: Taiho Pharmaceutical Company Limited. Active years: 1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Singh Rajeshwar. Retrieved from https://idiyas.com/inventor/singh-rajeshwar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Singh Rajeshwar: Innovator in Pharmaceutical Chemistry

Introduction

Singh Rajeshwar is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patent.

Latest Patents

Singh Rajeshwar holds a patent for 3-(7'-oxo-1'-aza-4'-oxabicyclo[3.2.0]-hept-3'-YL)propionic acid. This compound is a derivative of 3-(7'-oxo-1'-aza-4'-oxabicyclo[3.2.0]hept-3'-yl)propionic acid, represented by a complex formula involving various substituents. The patent highlights the versatility of the compound, which includes different functional groups that can be modified for various applications.

Career Highlights

Rajeshwar is currently employed at Taiho Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His work focuses on creating innovative solutions in the pharmaceutical industry, contributing to the development of new therapeutic agents.

Collaborations

Throughout his career, Singh Rajeshwar has collaborated with esteemed colleagues such as Toshiyuki Toko and Tomohiro Yamashita. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Singh Rajeshwar's contributions to pharmaceutical chemistry through his patent and collaborative efforts exemplify the spirit of innovation in the industry. His work continues to impact the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…